Citation	Primary Reason for Exclusion
Alshalalfa M, Tsai H, Haddad Z, Ross A, Karnes RJ, Davicioni E, et al. Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility. Journal of Clinical Oncology Conference. 2016;34(2 Suppl. 1).	Poster/abstract only
Bianconi M, Faloppi L, Mazzucchelli R, Giampieri R, Bittoni A, Del Prete M, et al. Multigene profiling in incidentally-and clinically detected prostate cancer. Ann Oncol. 2015;26:vi60.	Poster/abstract only
Bianconi M, Faloppi L, Zizzi A, Mazzucchelli R, Giampieri R, Bittoni A, et al. Multigene profiling in incidentally-and clinically detected prostate cancer. Eur J Cancer. 2015;51:S504–S5.	Poster/abstract only
Bianconi M, Faloppi L, Zizzi A, Mazzucchelli R, Scartozzi M, Montironi R, et al. Multigene profiling in incidentally-and clinically detected prostate cancer. Journal of Clinical Oncology Conference. 2015;33(15 Suppl. 1).	Poster/abstract only
Bishoff J, Freedland S, Schlomm T, Reid J, Brawer M, Stone S, et al. The CCP score provides significant prognostic information in Gleason score <7 patients. J Urol. 2016;195(4, Suppl):e18.	Poster/abstract only
Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192(2):409–14	Population (prostatectomy)
Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Welbourn W, Reid JE, et al. Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy. Journal of Clinical Oncology Conference. 2014;32(4 Suppl. 1).	Poster/abstract only
Bollito E, Manfredi M, Duregon E, Freschi M, Scattoni V, Papotti M, et al. The prognostic role of molecular testing in patients with prostate cancer: a preliminary study. Anticancer Res. 2013;33 (5):2301.	Poster/abstract only
Clar F, Bernet L, Morell L, Monserrat A, Lopez J, Gonzalvo V, et al. Retrospective study of gene prolaris (myriad genetics) signature in prostate biopsy from 29 patients with low and intermediate risk adenocarcinoma. European Urology, Supplements. 2014;13 (5):121.	Poster/abstract only
Cooperberg M, Freedland S, Schlomm T, Reid J, Stone S, Brawer M. Predicting radical prostatectomy outcome: CCP-CR score outperforms primary gleason grade among men with clinical Gleason <7 who are upgraded to Gleason 7. J Urol. 2014;191(4, Suppl):e937.	Poster/abstract only
Cooperberg MR, Simko J, Cowan JE, Reid JE, Bhatnagar S, Gutin A, et al. Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort. Journal of Clinical Oncology Conference. 2012;30(5 Suppl. 1).	Poster/abstract only
Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428–34.	Validation study
Crawford E, Shore N, Scardino P, Davis J, Tward JD, Moyes K, et al. CCP score stratifies risk for prostate cancer patients at biopsy: Initial commercial results. International Journal of Radiation Oncology Biology Physics. 2014;(1):S433.	Poster/abstract only
Crawford ED, Cole D, Lewine N, Gustavsen G. Evaluation of the economic impact of the CCP assay in localized prostate cancer. Journal of Clinical Oncology Conference. 2015;33(15 Suppl. 1) Poster/abstract only
Crawford ED, Kar AJ, Scholz MC, Fegan JE, Kaldate RR, Brawer MK. Cell cycle progression score to modify treatment decisions in prostate cancer: Results of an ongoing registry trial. Journal of Clinical Oncology Conference. 2014;32(15 Suppl. 1).	Poster/abstract only
Crawford ED, Shore N, Scardino PT, Davis JW, Tward JD, Harrison L, et al. CCP score and risk stratification for prostate cancer patients at biopsy. Journal of Clinical Oncology Conference. 2014;32(4 Suppl. 1).	Poster/abstract only
Crawford ED, Shore N, Scardino PT, Davis JW, Tward JD, Harrison L, et al. Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. Journal of Clinical Oncology Conference. 2015;33(7 Suppl. 1).	Poster/abstract only
Cuzick J, Berney DM, Fisher G, Mesher D, Moller H, Reid JE, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095–9.	Validation study
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382–9.	Validation study
Cuzick J, Stone S, Reid J, Fisher G, Moller H, Brawer M, et al. Patient AUA risk classification based on combined clinical cell cycle risk (CCR) score. J Urol. 2015;1):e3.	Poster/abstract only
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–55.	Validation study
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Lanchbury J, et al. Prognostic value of a cell cycle expression profile score among men with conservatively treated localized prostate cancer. Ann Oncol. 2010;21:viii63.	Poster/abstract only
Cuzick JM, Stone S, Fisher G, Hua Yang Z, North B, Berney D, et al. Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. Journal of Clinical Oncology Conference. 2014;32(15 Suppl. 1).	Poster/abstract only
Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, et al. Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. Journal of Clinical Oncology Conference. 2015;33(15 Suppl. 1).	Poster/abstract only
Davis JW, Crawford ED, Shore N, Scardino PT, Tward JD, Harrison L, et al. Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. Journal of Clinical Oncology Conference. 2015;33(15 Suppl. 1).	Poster/abstract only
Delouya G, Krishnan V, Bahary JP, Larrivee S, Taussky D. The cancer of the prostate risk assessment score predicts biochemical recurrence in intermediate-risk prostate cancer treated with EBRT dose escalation or LDR brachytherapy. Brachytherapy. 2014;13:S115–S6.	Poster/abstract only
Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. International Journal of Radiation Oncology Biology Physics. 2013;86(5):848–53.	Population (external beam radiation therapy)
Kar AJ, Scholz MC, Fegan JE, Crawford ED, Scardino PT, Kaldate RR, et al. The effect of cell cycle progression (CCP) score on treatment decisions in prostate cancer: Results of an ongoing registry trial. Journal of Clinical Oncology Conference. 2014;32(4 Suppl. 1).	Poster/abstract only
Kolquist KA, Cooperberg M, Freedland SJ, Schlomm T, Reid JE, Stone S, et al. Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score outperforms primary gleason grade among men with clinical Gleason <7 who are upgraded to Gleason 7. Lab Invest. 2014;94:241A.	Poster/abstract only
Kwiatkowski M, Daniele L, Albers P, Correa Generoso R, Angeles Cabeza M, McNeill A, et al. Potential reduction of over treatment of localized prostate cancer using a cell cycle gene expression assay (Prolaris) in biopsy specimens: results from the European multi-center EMPATHY-P study. Eur J Cancer. 2015;51:S505.	Poster/abstract only
Oderda M, Cozzi G, Barale M, Garelli G, Gurioli A, Daniele L, et al. CCP-score improves the current risk assessment in newly diagnosed prostate cancer patients. European Urology, Supplements. 2016;15 (3):e732.	Poster/abstract only
Porpiglia F, Sapino A, Daniele L, Albers P, Arsov C, Correa R, et al. European multi-centre study to assess the aggressiveness of prostate adenocarcinoma in newly-diagnosed patients using a cell-cycle gene expression assay (ProlarisTM) in biopsy specimens (EMPATHY-P Study). European Urology, Supplements. 2015;14 (2):e321–ea.	Poster/abstract only
Scardino PT, Cuzick JM, Stone S, Evans B, Jorgensen MR, Eastham JA, et al. Application of active surveillance threshold to series of samples submitted for commercial testing. Journal of Clinical Oncology Conference. 2016;34(2 Suppl. 1).	Poster/abstract only
Schlomm T, Sangale Z, Lanchbury J, Gutin A, Reid J, Graefen M, et al. Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology. Urology. 2013;1):S156.	Poster/abstract only
Shore N, Boczko J, Kella N, Moran BJ, Bianco FJ, Crawford ED, et al. Impact of CCP test on personalizing treatment decisions: results from a prospective registry of newly diagnosed prostate cancer patients. Journal of Clinical Oncology Conference. 2015;33(15 Suppl. 1).	Poster/abstract only
Shore N, Boczko J, Kella N, Moran BJ, Bianco FJ, Crawford ED, et al. Significant reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients in a large prospective registry. J Urol. 2015;1):e708.	Poster/abstract only
Shore N, Concepcion R, Saltzstein D, Lucia MS, Van Breda A, Welbourn W, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30(4):547–53.	Validation study
Warf MB, Reid JE, Brown KL, Kolquist KA, Stone S, Roa B. Analytical validation of a cell cycle progression signature used as a prognostic marker in prostate cancer. J Mol Biomark Diagn. 2015;6(4):1–5.	Validation study